SMAD2 and melanoma: Remarkably, several markers of this specific phenotype overlapped with our previously identified prognostic secretory signature (VEGFA, CCL20, TNF, Activin A), which proved to be triggered by melanoma cells via NFkB signaling pathway and sustained by the axis Activin A>Smad2/3 (13, 14, 19).